£3.7 million Acquisition for Arcis Biotechnology
Zeus Capital advises Arcis Biotechnology on its £3.7 million Acquisition of Altos Medical LLC and £2.8 million Fundraising
MANCHESTER and London-based corporate finance advisory firm Zeus Capital has advised Arcis Biotechnology on the £3.7 million acquisition of US based, Altos Medical LLC and a £2.8 million fundraising.
Arcis, which is based at Daresbury Innovation Centre, Warrington and headed by Peter Whitehurst, a former director at Scholl footwear and Durex condom giant SSL International, produces environmentally-friendly cleaning and germ-killing products for diverse markets and applications.
The Company is in discussions with several global companies keen to utilise its proprietary technology. It also includes in its product range an application for turf care which is already used by Premiership football clubs and international stadia.
Altos owns a complementary antimicrobial technology which enables the ultra-fast killing of particularly difficult pathogens such as C-Difficile, TB and Norovirus through cleansing and disinfection applications.
It has widespread potential in hospitals, dental surgeries and other public health facilities across the world and is already used in a number of countries.
Altos is profitable and already has a global distribution agreement with a major US medical distributor for the sale of its products into the medical and dental markets worldwide.
The acquisition of Altos will create a combined group that will be cash positive and cash generative, enabling faster development and commercialisation of other Arcis and Altos products to access significant markets.
This is the third transaction since December 2010 on which Zeus Capital have advised Arcis.
Tom Rowley, Director at Zeus Capital, said: "This is a transformational deal for Arcis. The enlarged group has an exciting range of products and, as a profitable and cash generative business, will stand out from many of its peers in the sector.”